News

An independent review of pharmacy benefit managers (PBMs) in Ohio indicates that PBM pricing practices likely contribute to rising health care costs.
A phase 2a study is evaluating cerdulatinib, an oral SYK/JAK inhibitor, in pre-treated patients with relapsed/refractory follicular lymphoma.
Top news of the day from across the health care landscape.
The new syringe is designed to improve the subcutaneous administration of lanreotide (Somatuline Depot, Ipsen Biopharmaceuticals).
The supplemental New Drug Application supports the expansion of niraparib’s indication as a late-line therapeutic option for patients with ovarian cancer.
Compared with nontargeted therapy, targeted therapies demonstrated a survival advantage for patients 65 years and older with metastatic renal cell carcinoma.
Receptor-modified T cells successfully controlled chronic hepatitis B virus, showing promise as a potential cure for the disease.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$